Zeiss Lightsheet 7 microscope

项目摘要 此申请是为购买蔡司光片7显微镜的资金。该仪器将 由UT Health San的光学成像核心设施（OIF）提供，管理和维护 安东尼奥（UT健康SA），这是由UT健康SA和梅斯癌症联合管理 中心OIF支持70个NIH资助的实验室。仅去年一年，OIF就支持了92 资助总额超过五千五百万元的研究项目。作为 梅斯癌症中心的一个组成部分，一个NCI指定的癌症中心，OIF收到了 在最近的NIH/NCI P30资助更新现场访问期间获得“杰出”评级。的类型 所要求的仪器目前在UT Health SA和任何其他机构都不可用， 圣安东尼奥市。这种新的成像模式的获取被认为是至关重要的， 为了使法语国家组织继续为我们的研究界提供所需的服务， 特别是，用于实现广泛的组织的快速、低毒性、高分辨率、三维成像， 一系列的标本为大量的NIH资助的研究项目。新仪器是 对提案中所列的主要用户尤其重要，这些用户具有很强的竞争力， 创新性研究取决于是否有这一工具。调查人员，包括 来自不同研究领域的成熟和新的研究将大大受益。新 科学仪器可以真正导致更好地了解基本的生物系统， 在治疗许多疾病状态，包括癌症，脑损伤， 退行性神经系统疾病、牙痛、视力疾病、骨质疏松症和骨丢失，以及 消化系统疾病这一新工具的可用性也将激励其他研究人员， UT Health SA和附近的机构将他们的研究转移到令人兴奋和高度竞争的领域。 新方向总的来说，这次收购无疑将对大量 美国国立卫生研究院资助的研究涵盖了生物医学研究领域的广泛学科。

Project Summary This request is for funds to purchase a Zeiss Light Sheet 7 microscope. This instrument will be housed, managed, and maintained by the Optical Imaging Core Facility (OIF) at UT Health San Antonio (UT Health SA), which is jointly managed by UT Health SA and the Mays Cancer Center. The OIF supports 70 NIH-funded laboratories. Last year alone, the OIF supported 92 externally funded research projects with a total award amount of more than $55 million. As a component of Mays Cancer Center, an NCI designated cancer center, the OIF received an “Outstanding” rating during the recent on site visit for the NIH/NCI P30 grant renewal. The type of instrument requested is currently unavailable at UT Health SA and at any other institutions in the city of San Antonio. The acquisition of this new imaging modality is considered essential in order for the OIF to continue providing the needed services to our research community, in particular, for achieving rapid, low toxicity, high-resolution, three-dimensional imaging of a broad range of specimens for a large number of NIH-funded research projects. The new instrument is particularly critical to the major users listed in the proposal, whose highly competitive and innovative research is dependent on the availability of this instrument. Investigators, including both well-established and new, from diverse research areas, will greatly benefit. The new instrument can truly lead to a better understanding basic biological systems and to develop novel therapeutic strategies in treating many diseases states, including cancer, brain injury, degenerative neurological disease, dental pain, vision disease, osteoporosis and bone loss, and digestive disease. The availability of this new instrument will also stimulate other investigators at UT Health SA and nearby institutions to move their research into exciting and highly competitive new directions. Overall, this acquisition will without a doubt, significantly impact a large number of NIH-funded investigations covering an expansive array of disciplines in biomedical research.